SCHEMBL563252

SCHEMBL563252

C#CCOCCOCCN

nearest known ligand 0.40

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122804 1.00 TSHR (0.40) TSHR
SCHEMBL31616404 1.00 TSHR (0.40) TSHR
SCHEMBL30724855 1.00 TSHR (0.40) TSHR
SCHEMBL1491293 1.00 TSHR (0.40) TSHR
SCHEMBL2552181 1.00 TSHR (0.40) TSHR
SCHEMBL18237339 1.00 TSHR (0.40) TSHR
SCHEMBL18089434 1.00 TSHR (0.40) TSHR
Hydrochloric Acid SCHEMBL25375836 0.97 TSHR (0.39) TSHR
SCHEMBL2818899 0.95
Hydrochloric Acid SCHEMBL25377147 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010096-A Carbon dot corrosion inhibitor with excellent corrosion inhibition and tracing performance, preparation method and application 中国石油大学(华东) 2026-05-12 CN claimed
CN-122010096-A Carbon dot corrosion inhibitor with excellent corrosion inhibition and tracing performance, preparation method and application 中国石油大学(华东) 2026-05-12 CN disclosed
CN-122010096-A Carbon dot corrosion inhibitor with excellent corrosion inhibition and tracing performance, preparation method and application 中国石油大学(华东) 2026-05-12 CN disclosed
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
US-20250345446-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES DRAUPNIR BIO APS (DK) 2025-11-13 US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 EP disclosed
EP-3743069-B1 BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT BIOVENTURES LLC (US) 2025-08-06 EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20120034295-A1 CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS YALE UNIVERSITY 2012-02-09 US disclosed
US-20110236311-A1 RADIOLABELLING METHODS HAMMERSMITH IMANET LIMITED (GB) 2011-09-29 US disclosed
US-7972588-B2 Radiolabelling methods HAMMERSMITH IMANET LIMITED (GB) 2011-07-05 US disclosed
US-20110021718-A1 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES (US) 2011-01-27 US disclosed
US-20100069609-A1 CHEMICAL METHODS AND APPARATUS ARSTAD ERIK 2010-03-18 US disclosed
US-20100040550-A1 RADIOLABELLING METHODS HAMMERSMITH IMANET LIMITED (GB) 2010-02-18 US disclosed
US-20090311177-A1 Radiolabelling Methods GE HEALTHCARE LIMITED (GB) 2009-12-17 US disclosed
US-20090286938-A1 SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-19 US disclosed
US-7601796-B2 polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions INTEZYNE TECHNOLOGIES, INC. (US) 2009-10-13 US disclosed
US-7560588-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2009-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885
US-20100040550-A1 RADIOLABELLING METHODS MPI, VIP, SLC40A1 TSHR 428/4885
US-20120034295-A1 CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS BRDT, PAICS, KLK3 TSHR 4176/4885
US-20110236311-A1 RADIOLABELLING METHODS MPI, VIP, FOLH1 TSHR 469/4885
US-20250345446-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES SORT1, SCARB1, LAMP1 TSHR 2269/4885
US-20090286938-A1 SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS PFAS, GFPT1, PFKFB4 TSHR 4718/4885
US-20090311177-A1 Radiolabelling Methods CTSV, NGLY1, MAN2B1 TSHR 273/4885
US-20100069609-A1 CHEMICAL METHODS AND APPARATUS C9, KDR, TIE1 TSHR 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.